Amid soaring global demand for glucagon-like peptide-1 (GLP-1) medications and widespread concerns about affordability and access, the World Health Organization (WHO) released its global comprehensive ...

The recommended use of GLP-1 therapies, including tirzepatide (Zepbound), semaglutide (Wegovy), and liraglutide (Saxenda), ...

The weight loss medications can be part of a long-term treatment strategy for adults, according to new World Health ...

The World Health Organization is officially backing popular weight-loss drugs like Ozempic and Wegovy. The WHO published new ...

Obesity is a chronic disease that can be treated with comprehensive and lifelong care, so people should not expect a one-time treatment through medication, the Taiwan Medical Association for the Study ...

New guidelines from the World Health Organization (WHO) recommend using GLP-1 medications to help manage obesity along with a ...

The World Health Organization (WHO) has issued its first-ever global guideline recommending that GLP-1 medicines (like those ...

This week, the World Health Organization entered a new arena with its first global guideline on GLP-1 therapies for obesity ...

To address soaring rates of childhood obesity, the American Academy of Pediatrics last year endorsed tactics it once considered risky. “Watchful waiting” had been standard practice, in part from ...

A new guideline from WHO conditionally recommends the use of GLP-1s to treat obesity as well as including the drugs as part ...

THE WORLD HEALTH ORGANISATION, or WHO, has issued global guidelines on the usage of GLP-1 medicines, also known as “skinny jabs,” in order to treat obesity. The announcement of the guidelines aims ...

Obesity has traditionally been considered a risk factor for various diseases. However, it is increasingly recognized as a disease by medical societies and governments. The 2020 Canadian Adult Obesity ...